Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

BACKGROUND: Diabetic macular oedema (DMO) may lead to visual loss and blindness. Several pharmacological treatments are available on the National Health Service (NHS) to United Kingdom patients affected by this condition, including intravitreal vascular endothelial growth factor inhibitors (anti-VEG...

Descripción completa

Detalles Bibliográficos
Autores principales: Pochopien, Michal, Beiderbeck, Annette, McEwan, Phil, Zur, Richard, Toumi, Mondher, Aballéa, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327492/
https://www.ncbi.nlm.nih.gov/pubmed/30626376
http://dx.doi.org/10.1186/s12913-018-3804-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327492/
https://www.ncbi.nlm.nih.gov/pubmed/30626376
http://dx.doi.org/10.1186/s12913-018-3804-4

Ejemplares similares